Sonoma Biotherapeutics has raised $265 million in new funding which will be used to advance its programs aiming to treat autoimmune and inflammatory conditions such as rheumatoid arthritis, type 1 diabetes, and IBD.
[GeekWire]
7992332
{7992332:nan}
apa
50
1
165427
https://www.stemcellsciencenews.com/wp-content/plugins/zotpress/
